Home > Insider Trading > Filing (0001181431-13-052840)

Filing Details

Accession Number:: 0001181431-13-052840
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2013-10-07 14:00:41
Reporting Period:: 2013-10-04

Filing Date:: 2013-10-07
Accepted Time:: 2013-10-07 14:00:41
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
1434316	Fate Therapeutics Inc	FATE	Biological Products, (No Disgnostic Substances) (2836)	000000000

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1219042	Robert Nelsen	C/O Arch Venture Partners 8725 West Higgins Road, Suite 290 Chicago IL 60631		Yes	No	Yes	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
Common Stock	Acquisiton	2013-10-04	1,246,156	$0.00	1,246,156	No	4	C	Indirect	By ARCH Venture Fund VI, L.P.
Common Stock	Acquisiton	2013-10-04	265,252	$0.00	1,511,408	No	4	C	Indirect	By ARCH Venture Fund VI, L.P.
Common Stock	Acquisiton	2013-10-04	128,447	$6.00	1,639,855	No	4	J	Indirect	By ARCH Venture Fund VI, L.P.
Common Stock	Acquisiton	2013-10-04	833,333	$6.00	2,473,188	No	4	P	Indirect	By ARCH Venture Fund VI, L.P.

Equity Swap Involved	Form Type	Code	Nature of Ownership	Explanation
No	4	C	Indirect	By ARCH Venture Fund VI, L.P.
No	4	C	Indirect	By ARCH Venture Fund VI, L.P.
No	4	J	Indirect	By ARCH Venture Fund VI, L.P.
No	4	P	Indirect	By ARCH Venture Fund VI, L.P.

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Series A Convertible Preferred Stock	Disposition	2013-10-04	675,493	$0.00	675,493	$0.00
Common Stock	Series B Convertible Preferred Stock	Disposition	2013-10-04	230,769	$0.00	265,252	$0.00
Common Stock	Series C Convertible Preferred Stock	Disposition	2013-10-04	570,663	$0.00	570,663	$0.00

Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
No	4	C	Indirect
No	4	C	Indirect
No	4	C	Indirect

Footnotes

The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Persons converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on a 1-for-1 basis.
The aggregate number of shares of Issuer's Preferred Stock held by the Reporting Persons converted into Common Stock immediately prior to the closing of the Issuer's initial public offering and has no expiration date. These shares converted into Common Stock on approximately a 1-for-1.15 basis.
These shares are owned directly by ARCH Venture Fund VI, L.P. ("ARCH Fund VI"). The sole general partner of ARCH Fund VI is ARCH Venture Partners VI, L.P. ("ARCH Partners VI"). The sole general partner of ARCH Partners VI is ARCH Venture Partners VI, LLC ("ARCH VI LLC"). The Managing Directors of ARCH VI LLC, Robert T. Nelsen, Keith Crandell and Clinton Bybee, are deemed to have voting and dispositive power over the shares and may be deemed to beneficially own certain shares held by ARCH Fund VI. Each Reporting Person disclaims beneficial ownership of these securities, except to the extent of his pecuniary interest therein, and this report shall not be deemed an admission that such Reporting Persons are the beneficial owners of such securities for Section 16 or any other purpose.
The shares were acquired upon conversion of a convertible promissory note exempt from the definition of a derivative security because the conversion price did not become fixed until automatic conversion at the time of the closing of the Issuer's initial public offering.